The Freiburg spinout has secured an undisclosed amount from Aesculap that is said to be one of the largest corporate venturing investments in a German spinout to date.
Neuroloop, a spinout from Albert Ludwig University of Freiburg working on a new way to lower blood pressure, has raised an undisclosed amount from Aesculap, a supplier of medical technology products and services.
Although the size was unconfirmed, Germany-based legal advice firm Orrick, which advised Aesculap on the transaction, reported that the deal is “one of the largest corporate venture capital investments” in a spinout in Germany to date.
Neuroloop is developing neurostimulators that can be used to reduce blood pressure. The technology is based on research at the university’s Institute for Microsystems Engineering and University Hospital Freiburg.
Neuroloop was supported by the Central Department for Technology Transfer at the university.
Aesculap is a wholly-owned subsidiary of Germany-based medical and pharmaceutical device company B. Braun Melsungen. The investments marks Aesculap’s first corporate venturing deal.
Boris Hofmann, team manager business development at Aesculap, said: “With its participation, Aesculap gained a beachhead in the functional neurosurgery which is an increasingly important part of the neurosurgery field and which is expected to see rapid developments market over the next years.”
